Industry News
Cohort 1 lung bronchoscopy sample results demonstrate widespread delivery and expression of the 4D-710 CFTR∆R transgene in 100% of samples from all three patients Cohort 1 safety and tolerability of 4D-710 demonstrated to date, with no drug-related adverse events following aerosol delivery Cohort 1 enrollment completed; Cohort 2 enrollment on-going Conference call & webcast to…
Read More
TruGraf® Liver is a novel gene expression biomarker diagnostic test used to confirm immune quiescence and rule out organ rejection for liver transplant recipients. Excerpt from the Press Release: FRAMINGHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ transplant outcomes worldwide, will be attending The…
Read More
Biomarker data demonstrates proof-of-concept for KP104’s dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies Excerpt from the Press Release: CAMBRIDGE, Mass., Nov. 3, 2022 /PRNewswire/ — Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today presented…
Read More
In healthy volunteers, OCE-205 administration led to increases in mean arterial pressure with promising safety profile Study findings support clinical program for OCE-205 in End-Stage Liver Disease focused on treating consequences associated with complications of portal hypertension, such as HRS-AKI and ascites Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Ocelot Bio, Inc., a clinical-stage biopharmaceutical…
Read More
3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose Standards Excerpt from the Press Release: MARLBOROUGH, Mass.–(BUSINESS WIRE)–Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that its 3Dimensions™ mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening…
Read More
– Two patients exhibited an unconfirmed partial response at their first scan, and two additional patients saw promising tumor regression activity out of ten efficacy evaluable patients, demonstrating monotherapy activity of milademetan in MDM2-amplified patients – – Drug safety profile of milademetan preliminarily consistent with prior Phase 1 trial – – Protocol amendment planned to…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease, today announced new preclinical data demonstrating proof-of-concept for AB359 as a novel immunotherapy approach for chronic HBV. AB359 is…
Read More
Reductions in hepatitis B surface antigen levels observed in a subset of subjects with chronic hepatitis B enrolled in Phase 1 study ALG-000184-201 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address…
Read More
Compelling data with STAR0602 demonstrates potent, single agent anti-tumor activity in PD-1 refractory solid tumor models Distinct mechanism of action through expansion of a subset of Vβ T cells with a novel memory phenotype that promotes durable de novo antitumor immune responses STAR0602 slated to initiate Phase 1/2 clinical trial (START-001) in the fourth quarter…
Read More
– Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design – Excerpt from the Press Release: BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time…
Read More